The company’s shares closed last Friday at $1.64, close to its 52-week low of $1.10.
According to TipRanks.com, Raja is a 2-star analyst with an average return of 1.0% and a 34.2% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Oncternal Therapeutics, and Caladrius Biosciences.
Currently, the analyst consensus on BioCardia is a Strong Buy with an average price target of $4.67, which is a 188.3% upside from current levels. In a report issued on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
BioCardia’s market cap is currently $24.63M and has a P/E ratio of -2.11.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Read More on BCDA: